
Cycurion, Nuwellis, T1 Energy, FREYR Battery, GlucoTrack, Bitfarms, and Capricor Therapeutics are the seven Penny stocks to watch today, according to MarketBeat’s stock screener tool. Penny stocks are shares of small or developing companies that typically trade at very low prices, often below $5 per share, and may be listed on over-the-counter markets rather than major exchanges. They are generally less liquid and more volatile than established stocks, making them higher-risk investments that may also be more susceptible to fraud and price manipulation. These companies had the highest dollar trading volume of any Penny stocks within the last several days.
Cycurion (CYCU)
Read Our Latest Research Report on CYCU
Nuwellis (NUWE)
Read Our Latest Research Report on NUWE
T1 Energy (TE)
T1 Energy Inc. is an energy solutions provider building an integrated supply chain for solar and batteries. T1 Energy Inc. , formerly known as FREYR Battery, is based in NEW YORK.
Read Our Latest Research Report on TE
FREYR Battery (FREY)
Read Our Latest Research Report on FREY
GlucoTrack (GCTK)
GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.
Read Our Latest Research Report on GCTK
Bitfarms (BITF)
Bitfarms Ltd. engages in the mining of cryptocurrency coins and tokens in Canada, the United States, Paraguay, and Argentina. It owns and operates server farms that primarily validates transactions on the Bitcoin Blockchain and earning cryptocurrency from block rewards and transaction fees. The company also provides electrician services to commercial and residential customers in Quebec, Canada.
Read Our Latest Research Report on BITF
Capricor Therapeutics (CAPR)
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Read Our Latest Research Report on CAPR
Recommended Stories
- MarketBeat’s Top Five Stocks to Own in July 2026
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
- Tesla: After a Rough Quarter, 2 Very Different Futures Come Into Focus
